MXPA01005971A - Metodo para el tratamiento de la isquemia cerebral y el uso de la eritropoyetina o derivados de la eritropoyetina para el tratamiento de la isquemia cerebral. - Google Patents
Metodo para el tratamiento de la isquemia cerebral y el uso de la eritropoyetina o derivados de la eritropoyetina para el tratamiento de la isquemia cerebral.Info
- Publication number
- MXPA01005971A MXPA01005971A MXPA01005971A MXPA01005971A MXPA01005971A MX PA01005971 A MXPA01005971 A MX PA01005971A MX PA01005971 A MXPA01005971 A MX PA01005971A MX PA01005971 A MXPA01005971 A MX PA01005971A MX PA01005971 A MXPA01005971 A MX PA01005971A
- Authority
- MX
- Mexico
- Prior art keywords
- erythropoietin
- treatment
- use according
- paralysis
- human
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 63
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 63
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 63
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000006011 Stroke Diseases 0.000 claims abstract description 7
- 201000006474 Brain Ischemia Diseases 0.000 claims description 21
- 206010033799 Paralysis Diseases 0.000 claims description 21
- 206010008118 cerebral infarction Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 8
- 230000002093 peripheral effect Effects 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract 2
- 210000005013 brain tissue Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 6
- 102100031939 Erythropoietin Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 5
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 5
- 102000044890 human EPO Human genes 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857609A DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| PCT/EP1999/009864 WO2000035475A2 (de) | 1998-12-14 | 1999-12-13 | Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01005971A true MXPA01005971A (es) | 2002-03-27 |
Family
ID=7891015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01005971A MXPA01005971A (es) | 1998-12-14 | 1999-12-13 | Metodo para el tratamiento de la isquemia cerebral y el uso de la eritropoyetina o derivados de la eritropoyetina para el tratamiento de la isquemia cerebral. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7514072B1 (enExample) |
| EP (1) | EP1140139B2 (enExample) |
| JP (2) | JP4750947B2 (enExample) |
| KR (1) | KR100774827B1 (enExample) |
| CN (1) | CN1187085C (enExample) |
| AT (1) | ATE253932T1 (enExample) |
| AU (1) | AU766216C (enExample) |
| BG (1) | BG65417B1 (enExample) |
| BR (1) | BR9916197A (enExample) |
| CA (1) | CA2353553C (enExample) |
| DE (2) | DE19857609A1 (enExample) |
| DK (1) | DK1140139T4 (enExample) |
| ES (1) | ES2211218T5 (enExample) |
| HK (1) | HK1042655B (enExample) |
| HU (1) | HUP0104709A3 (enExample) |
| ID (1) | ID29107A (enExample) |
| IL (2) | IL143579A0 (enExample) |
| MX (1) | MXPA01005971A (enExample) |
| NO (1) | NO330079B1 (enExample) |
| NZ (1) | NZ541591A (enExample) |
| PL (1) | PL202483B1 (enExample) |
| PT (1) | PT1140139E (enExample) |
| RO (1) | RO121409B1 (enExample) |
| RU (1) | RU2242991C2 (enExample) |
| WO (1) | WO2000035475A2 (enExample) |
| ZA (1) | ZA200104626B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| TR200103785T2 (tr) * | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7048934B2 (en) | 2001-08-30 | 2006-05-23 | Stem Cell Therapeutics Inc. | Combined regulation of neural cell production |
| ES2383169T3 (es) * | 2001-09-14 | 2012-06-18 | Stem Cell Therapeutics Inc. | Aumento del número de células madre neurales inducido por prolactina y uso terapéutico del mismo |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| AU2003273615B2 (en) * | 2002-06-11 | 2010-07-29 | Brigham And Women's Hospital | Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| EP1633383A4 (en) * | 2003-03-27 | 2008-05-21 | Janssen Pharmaceutica Nv | USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| AU2004277954A1 (en) | 2003-09-29 | 2005-04-14 | The Kenneth S Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| PL1675573T4 (pl) * | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
| WO2005077404A1 (en) * | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
| EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| AU2006297041A1 (en) | 2005-09-27 | 2007-04-05 | Stem Cell Therapeutics Corp. | Oligodendrocyte precursor cell proliferation regulated by prolactin |
| US8333974B2 (en) * | 2006-03-17 | 2012-12-18 | Stem Cell Therapeutics Corp. | Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents |
| WO2007142288A1 (ja) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | エリスロポエチンを用いた虚血性疾患の治療 |
| NO2170279T3 (enExample) | 2007-07-31 | 2018-05-26 | ||
| RU2446834C2 (ru) * | 2010-06-15 | 2012-04-10 | Елена Александровна Лебедева | Способ лечения пострадавших с сочетанной черепно-мозговой травмой |
| WO2012148200A2 (ko) | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
| RU2495688C1 (ru) * | 2012-03-28 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" | Способ лечения ишемии головного мозга в эксперименте |
| US9610444B2 (en) | 2013-03-15 | 2017-04-04 | Pacesetter, Inc. | Erythropoeitin production by electrical stimulation |
| KR20190052855A (ko) | 2017-11-09 | 2019-05-17 | 대한제당 주식회사 | 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
| RU2128227C1 (ru) | 1989-12-22 | 1999-03-27 | Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) | Способ активации транскрипционно-молчащего гена |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| JP3537151B2 (ja) * | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| RU2068268C1 (ru) * | 1992-03-19 | 1996-10-27 | Учебно-научный центр Медицинского центра при Правительстве РФ | Способ профилактики церебро-васкулярных заболеваний |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| FI955128L (fi) | 1993-04-29 | 1995-10-27 | Abbott Lab | Erytropoietiinianalogikoostumuksia ja menetelmä niiden valmistamiseksi ja käyttämiseksi |
| IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
| SE520730C2 (sv) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
-
1998
- 1998-12-14 DE DE19857609A patent/DE19857609A1/de not_active Ceased
-
1999
- 1999-12-13 IL IL14357999A patent/IL143579A0/xx active IP Right Grant
- 1999-12-13 HU HU0104709A patent/HUP0104709A3/hu unknown
- 1999-12-13 DE DE59907752T patent/DE59907752D1/de not_active Expired - Lifetime
- 1999-12-13 PL PL349335A patent/PL202483B1/pl not_active IP Right Cessation
- 1999-12-13 BR BR9916197-4A patent/BR9916197A/pt not_active Application Discontinuation
- 1999-12-13 AT AT99966958T patent/ATE253932T1/de active
- 1999-12-13 ES ES99966958T patent/ES2211218T5/es not_active Expired - Lifetime
- 1999-12-13 JP JP2000587794A patent/JP4750947B2/ja not_active Expired - Fee Related
- 1999-12-13 RU RU2001116077/14A patent/RU2242991C2/ru not_active IP Right Cessation
- 1999-12-13 PT PT99966958T patent/PT1140139E/pt unknown
- 1999-12-13 CN CNB998160474A patent/CN1187085C/zh not_active Expired - Fee Related
- 1999-12-13 HK HK02104485.2A patent/HK1042655B/zh not_active IP Right Cessation
- 1999-12-13 KR KR1020017007421A patent/KR100774827B1/ko not_active Expired - Fee Related
- 1999-12-13 MX MXPA01005971A patent/MXPA01005971A/es active IP Right Grant
- 1999-12-13 DK DK99966958T patent/DK1140139T4/da active
- 1999-12-13 CA CA2353553A patent/CA2353553C/en not_active Expired - Fee Related
- 1999-12-13 US US09/868,089 patent/US7514072B1/en not_active Expired - Fee Related
- 1999-12-13 EP EP99966958A patent/EP1140139B2/de not_active Expired - Lifetime
- 1999-12-13 ID IDW00200101535A patent/ID29107A/id unknown
- 1999-12-13 RO ROA200100684A patent/RO121409B1/ro unknown
- 1999-12-13 WO PCT/EP1999/009864 patent/WO2000035475A2/de not_active Ceased
- 1999-12-13 AU AU22831/00A patent/AU766216C/en not_active Ceased
- 1999-12-13 NZ NZ541591A patent/NZ541591A/en not_active IP Right Cessation
-
2001
- 2001-06-05 IL IL143579A patent/IL143579A/en not_active IP Right Cessation
- 2001-06-06 ZA ZA200104626A patent/ZA200104626B/en unknown
- 2001-06-07 BG BG105575A patent/BG65417B1/bg unknown
- 2001-06-12 NO NO20012896A patent/NO330079B1/no not_active IP Right Cessation
-
2010
- 2010-12-20 JP JP2010283105A patent/JP2011079860A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2353553C (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| JP5785008B2 (ja) | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 | |
| IE64080B1 (en) | Pharmaceutical for subcutaneous administration containing polypeptides | |
| US20040209812A1 (en) | Use of erythropoietin in stroke recovery | |
| Eidemak et al. | Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD | |
| Park et al. | Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat | |
| US7232797B2 (en) | Erythropoietin dosing regimen for treating anemia | |
| US8946161B2 (en) | Method of treatment using stable liquid formulation of G-CSF | |
| JPH03190823A (ja) | エリスロポエチン皮下又は筋肉投与剤 | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| CA2195345A1 (en) | Use of (s)-adenosyl-l-methionine (same) and its physiologically compatible salts for treating reperfusion damage triggered by temporary focal ischaemia | |
| US20060166885A1 (en) | Treatment and prevention of decubitus | |
| CN109865127B (zh) | 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途 | |
| AVAKOV et al. | Pathophysiology and differentiated hyperosmolary therapy in cerebral edema in patients with craniocerebral injury. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |